TICKERNERD
Menu
ACTUACTUHealthcare · Biotechnology

ACTU Stock Forecast: Actuate Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.34
−9.68% on the day

The 3 Wall Street analysts covering Actuate Therapeutics, Inc. hold a median 12-month price target of $12 — +3481.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.0M
Ticker Nerd rank
32/ 100
Median analyst target
$12
Analysts covering
3
Revenue$0.0
Operating income−$4.9M
Net income−$4.9M
Free cash flow−$4.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.5%
1M
−57.0%
YTD
−94.5%
1Y
−94.9%
From 52W high
−95.6%
From 52W low
0.0%
$0.34
$7.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACTU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Actuate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
32/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Growth
81
Revisions
62
Issuance
40
Accruals
35
Value
22
Volatility
21
Quality
13
Momentum
9

Size (92): Smaller than most of the companies we track.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACTU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACTU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26ACTUHigh $15Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $8Median $12High $15

The green dot is the last close — the median target sits +3481.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$15
30 July 2026Rodman & RenshawInitiatesBuy$6.00
30 July 2026Rodman & RenshawInitiatesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy$15
18 May 2026HC Wainwright & Co.ReiteratesBuy—
22 Apr 2026HC Wainwright & Co.ReiteratesBuy—
13 Apr 2026HC Wainwright & Co.MaintainsBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
23 Sept 2025HC Wainwright & Co.ReiteratesBuy—
26 Aug 2025B. Riley SecuritiesInitiatesBuy—
18 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ACTU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACTU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Actuate Therapeutics, Inc. returned −94.9% against +12.4% for the S&P 500, dividends included.

ACTU vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ACTUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACTU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Actuate Therapeutics, Inc. (ACTU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.8×

Cheaper than 63% of US stocks

Price / sales
—
Price / book
8.2×

Cheaper than 11% of US stocks

EV / EBITDA
−0.2×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−280.5%

Higher than 5% of US stocks

Return on assets
−213.4%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Actuate Therapeutics, Inc. (ACTU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Actuate Therapeutics, Inc. has a market value of $8.0M and an enterprise value of $3.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$20.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.8M.

  • Shares outstanding: 24.0M.

  • Trailing P/E: 6.8×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Actuate Therapeutics, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

ACTU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACTUActuate Therapeutics, Inc.$8.0M32
CURXCuranex Pharmaceuticals, Inc.$8.1M7
ENSCEnsysce Biosciences, Inc.$8.2M29
TOVXTheriva Biologics, Inc.$7.8M46
CLGNCollPlant Biotechnologies Ltd.$7.8M29
MBRXMoleculin Biotech, Inc.$8.3M25
SNGXSoligenix, Inc.$7.7M32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Actuate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACTU news & analysis

Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

GlobeNewsWire · 27 Oct 2026neutral

Actuate Therapeutics priced an underwritten public offering of 30,985,900 common shares and warrants to purchase up to 15,492,950 additional shares, at $0.71 per set of two shares and one warrant. The warrants have a $0.45 exercise price, are immediately exercisable, and expire five years after issuance.

Why it matters — The offering terms outline a potential source of capital for Actuate and include warrants that could result in additional shares if exercised.

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 9 Sept 2026neutral

Actuate Therapeutics announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York City. The management team will also be available for one-on-one meetings during the conference.

Why it matters — An ACTU watcher would care because the presentation offers an opportunity for the company's management to communicate its clinical-stage cancer therapy development to investors at a notable industry conference.

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

GlobeNewsWire · 9 Sept 2026positive

Actuate Therapeutics announced new preclinical data showing synergistic activity of elraglusib in combination with the investigational RAS inhibitors zoldonrasib and daraxonrasib in pancreatic ductal adenocarcinoma, including models resistant to FOLFIRINOX chemotherapy. The studies were conducted in collaboration with investigators at Northwestern University and the Mayo Clinic.

Why it matters — The promising preclinical results may support further development of elraglusib combination therapy for difficult-to-treat pancreatic cancer.

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

Zacks Investment Research · 2 Sept 2026positive

Zacks Investment Research upgraded Actuate Therapeutics, Inc. (ACTU) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects, which the report suggests could drive the stock higher in the near term.

Why it matters — The upgrade signals a more favorable analyst view of ACTU's earnings outlook and could influence how investors assess the stock's near-term prospects.

FAQ

Frequently asked questions about ACTU stock

What is the ACTU stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Actuate Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACTU stock a buy right now?

Of the 3 analysts covering Actuate Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actuate Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACTU?

As at 31 Oct 2026, Actuate Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will ACTU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +3481.0% from the last close, and Ticker Nerd's factor model ranks Actuate Therapeutics, Inc. 32 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACTU stock forecast for 2030?

No analyst covering Actuate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $15 over the next 12 months.

How has ACTU stock performed over the past year?

Actuate Therapeutics, Inc. returned -94.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Actuate Therapeutics, Inc. do?

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers.

What is the latest news on ACTU?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering". Actuate Therapeutics priced an underwritten public offering of 30,985,900 common shares and warrants to purchase up to 15,492,950 additional shares, at $0.71 per set of two shares and one warrant. The warrants have a $0.45 exercise price, are immediately exercisable, and expire five years after issuance.

Company

About Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers. The company’s work is aimed at targeting cancer pathways involved in tumor growth, survival, and resistance to standard treatments. Actuate Therapeutics also explores applications in cancer types and related disease areas where conventional options remain limited, positioning it within the oncology drug development segment of the healthcare market. Headquartered in Fort Worth, Texas, Actuate Therapeutics concentrates on advancing investigational medicines through early and mid-stage development, with a business model built around translational research, clinical testing, and potential future commercialization of targeted therapies.

CEO Mr. Daniel M. Schmitt · 12 employees · United States · https://actuatetherapeutics.com